{"pub": "investing.com", "url": "https://au.investing.com/news/stock-market-news/briefclinuvel-pharmaceuticals-says-tga-granted-priority-registration-pathway-for-scenesse-1982035", "downloaded_at": "2019-10-30 09:57:19.714475+00:00", "title": "BRIEF-Clinuvel Pharmaceuticals Says TGA Granted Priority Registration Pathway For SCENESSE", "language": "en", "text": "BRIEF-Clinuvel Pharmaceuticals Says TGA Granted Priority Registration Pathway For SCENESSE\n\nStock Markets 15 minutes ago (Oct 30, 2019 20:42)\n\n\u00a9 Reuters. BRIEF-Clinuvel Pharmaceuticals Says TGA Granted Priority Registration Pathway For SCENESSE Oct 30 (Reuters) - Clinuvel Pharmaceuticals Ltd : * AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION GRANTED SCENESSE RIGHT TO BE FILED UNDER PRIORITY REGISTRATION PROCESS * CLINUVEL INTENDS TO SUBMIT SCIENTIFIC DOSSIER IN Q1 2020 * SCENESSE TO TREAT PATIENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP) IN AUSTRALIA\n\nBRIEF-Clinuvel Pharmaceuticals Says TGA Granted Priority Registration Pathway For SCENESSE", "description": "BRIEF-Clinuvel Pharmaceuticals Says TGA Granted Priority Registration Pathway For SCENESSE", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXMPEB3R08Z_L.jpg", "published_at": "2019-10-30"}